SARS-CoV-2 Antibody Rapid Test
- UID
- MFG/IVD/2023/000113_d369ba60683bfbff2f4f15d5c84f4ea0_546f73f25c6b5ded63db70367835bc49
- Device class
- Class B
- Brand name
- Chimera
- License holder
- CHIMERA BIOTECH PRIVATE LIMITED
- Approving authority
- South Delhi Division
- Product information
- The Chimera® SARS-CoV-2 Antibody Rapid is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies to SARS-CoV-2 in human Whole Blood/Serum/Plasma. It provides an aid in the diagnosis of infection with SARS-CoV-2. Prolonged fever, fatigue, headache, cough, shortness of breathing, nausea, sore throat, loss of taste or smell, congestion or runny nose and diarrhoea
SARS-CoV-2 Antibody Rapid Test is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2023/000113_d369ba60683bfbff2f4f15d5c84f4ea0_546f73f25c6b5ded63db70367835bc49. This device is marketed under the brand name Chimera. The license holder is CHIMERA BIOTECH PRIVATE LIMITED, and it is classified as Device Class Class B. The approving authority is South Delhi Division.
This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.